Research to be presented concerning Bexxar® at the American Society of Hematology Annual Meeting

Research to be presented concerning Bexxar® (Tositumomab and Iodine I 131 Tositumomab) an investigational radioimmunotherapy being studied for the treatment of low-grade or transformed low-grade non-Hodgkin’s lymphoma (NHL) includes:

Contact: Julie McQuain (212) 477-0472

Sunday, December 9, 2001

[1433] Acute and Delayed Hematologic Toxicities Associated with Bexxar® Therapy Are Modest: Overall Experience in Patients with Low-Grade and Transformed Low-Grade NHL.
Date: Sunday, December 9, 2001 Time: 10:00 am Location: Hall C,
Poster Board Number 538

Monday, December 10, 2001

[2527] Bexxar® (Tositumomab and Iodine I 131 Tositumomab) Results in Durable Long-Term Responses in Patients with Poor Prognosis, Multiple Relapsed (Rel), and Refractory (Ref) Low-Grade or Transformed Low-Grade Non-Hodgkins Lymphoma (NHL).
Date: Monday, December 10, 2001 Time: 10:00 am Location: Hall C,
Poster Board Number 512

Tuesday, December 11, 2001

[3503] Results of a Randomized Study of Bexxar® (Tositumomab and Iodine I 131 Tositumomab) vs. Unlabeled Tositumomab in Patients with Relapsed or Refractory Low-Grade or Transformed Non-Hodgkin's Lymphoma (NHL).
Date: Tuesday, December 11, 2001 Time: 8:45 am Location: Hall F-5

[3505] Triple Modality Therapy for Follicular Low-Grade Lymphoma: Initial Treatment with Fludarabine Followed by Bexxar® (Tositumomab and Iodine I 131 Tositumomab).
Date: Tuesday, December 11, 2001 Time 9:15 am Location: Hall F-5